June 25, 2020
RFA-CA-20-038 - Emergency Awards: SARS-CoV-2 Serological Sciences Centers of Excellence (U54 Clinical Trial Optional)
RFA-CA-20-039 - Emergency Awards: Research Projects in SARS-CoV-2 Serological Sciences (U01 Clinical Trial Optional)
National Cancer Institute (NCI)
Leidos Biomedical Research, Inc. (Leidos Biomed) has issued an RFP for Capacity Building Centers to support the Serological Sciences Network (SeroNet), developed to mobilize collaborative efforts to develop serological assays of high specificity and high sensitivity for deployment to test for SARS-CoV-2 induced immune responses and to rapidly expand national serological testing capacity.
The CBCs shall focus on the rapid deployment and expansion of SARS-CoV-2 serological testing capacity and practice and provide opportunities for focused studies in serological sciences technology innovation and research, including serosurveillance. In addition to the CBCs, SeroNet includes Centers of Excellence, Research Projects, and the Frederick National Laboratory for Cancer Research (FNLCR) Serology Laboratory. Each SeroNet component is expected to interact closely, collaborate, and share data, resources, and samples. The Serological Sciences Network Coordinating Center (SSNCC) at FNLCR will manage and coordinate data and communications across SeroNet, and a Steering Committee comprised of members from each component, including NCI and NIAID, will provide scientific oversight and guidance.
The objective of the CBC is to address unmet needs in SARS-CoV-2 serological testing: 1) standardization, 2) assay development, and 3) availability of large-scale testing to identify those who may have been infected or exposed to the virus. Applications from academic centers who want to both provide testing and undertake research studies related to serological science, serosurveillance, or the development of assays are encouraged.
Scope of Work includes:
1. Acquire and conduct quality control assessments of critical reference samples, according to standard operating procedures developed and shared with the SSNCC
2. Acquire scalable serological testing capability for SARS-CoV-2 infection using a high-quality serological assay, with high specificity and high sensitivity
3. Scale-up acquired high-quality serological testing to provide increased national capacity
4. Collaborate in SeroNet activities
5. Collaborate in serosurveillance and sero-protection studies, including longitudinal studies that will investigate the dynamics of serological responses to SARS-CoV-2 infection
6. Propose and pursue focused studies in serological sciences technology innovation and enhancement
The Solicitation is anticipated to result in four (4) to eight (8) CBCs. Awards are anticipated in September 2020 to Offerors capable of performing the work described in the statement of work available by request through beta.sam.gov (internet address above).
This advertisement does not commit Leidos Biomed and/or the United States Federal Government to award any contract. The NAICS code for this acquisition is 541715.
Place of Performance:
The majority of the work will be performed at the Offeror’s facilities; however, the Leidos Biomed technical project manager may ask that specific tasks, such as testing and demonstrations, be performed at other locations.
The RFP Solicitation S20-119 is only available electronically and must be accessed through Frederick National Lab: https://frederick.cancer.gov/workwithus/solicitations/s20-119 or through beta.sam.gov. All information required for submission of a proposal will be contained in the electronic Solicitation Package. No collect calls will be accepted. No facsimile transmissions will be accepted. It is the Offerors responsibility to monitor the sites mentioned above for the release of any amendments. All responsible sources may submit a proposal, which shall be considered by Leidos Biomed.
POTENTIAL OFFERORS WILL BE RESPONSIBLE FOR DOWNLOADING THEIR OWN COPY OF THE SOLICITATION AND ANY AMENDMENTS THAT MAY BE ISSUED. FAILURE TO DO SO WILL BE AT THE OFFEROR’S OWN RISK. ALL INQUIRIES SHALL BE SUBMITTED ELECTRONICALLY TO THE LEIDOS BIOMED SUBCONTRACTS ADMINISTRATOR LISTED AS THE POINT OF CONTACT BELOW.
Contracting Office Address:1050 Boyle Street, Frederick, MD 21702
Leidos Biomedical Research, Inc.